2020 | |
---|---|
Criterium: | Position: |
Overall Score: | > 1000 |
Total Project Funding per Partner: | > 1000 |
Total Number of Projects: | > 1000 |
2019 | |
Criterium: | Position: |
Overall Score: | > 1000 |
Total Project Funding per Partner: | > 1000 |
Total Number of Projects: | > 1000 |
2015 | |
Criterium: | Position: |
Overall Score: | > 1000 |
Networking Rank (Reputation): | > 1000 |
2012 | |
Criterium: | Position: |
Overall Score: | 900-1000 |
Networking Rank (Reputation): | > 1000 |
Networking Rank (Reputation): | > 1000 |
2008 | |
Criterium: | Position: |
Overall Score: | > 1000 |
Networking Rank (Reputation): | > 1000 |
Total number of projects: 7
As coordinator: 0
As participant: 7
Sole participant: 0
Coordinator / Participant Ratio: 0*
Total project funding [€]: | Projects [No]: | |||||
---|---|---|---|---|---|---|
Year: | coordinator* | participant* | per partner | as coordinator | as participant | |
2020 | 0 | 1.879.216 | 11.875 | 1 | ||
2019 | 0 | 8.391.240 | 861.250 | 1 | ||
2017 | 0 | 10.599.993 | 108.993 | 1 | ||
2015 | 0 | 5.825.580 | 705.250 | 1 | ||
2013 | 0 | 5.986.903 | 1.541.187 | 1 | ||
2012 | 0 | 6.549.575 | 601.945 | 2 |
Total number of partners: 93
Partner loyalty:
Frequent Partner: (> 2 projects): 12
Rare Partner: 81
Frequent / Rare Partner Ratio: 0.15
Start date | Project | acronym | role | funding | partners |
---|---|---|---|---|---|
2020-06-01 | DESIGN STUDY FOR A EUROPEAN VACCINE INFRASTRUCTURE | TRANSVAC-DS | participant | 1.879.216 | 28 |
2019-06-01 | Vaccine for prevention and treatment of Trypanosoma cruzi infection | CRUZIVAX | participant | 8.391.240 | 11 |
2017-05-01 | European Vaccine Research and Development Infrastructure | TRANSVAC2 | participant | 10.599.993 | 26 |
2015-03-01 | Sustainable downstream processing of vaccines through incorporation of nanobiotechnologies : novel affinity ligands and biomimetic membranes | DiViNe | participant | 5.825.580 | 6 |
2013-01-01 | Human monoclonal antibody therapy to prevent hepatitis C virus reinfection of liver transplants: advancing lead monoclonal antibodies into clinical trial | HEPAMAB | participant | 5.986.903 | 7 |
2012-11-01 | "From Brain Gene Transfer Towards Gene Therapy: Pharmacological Assessment of AAV, CAV and LVV" | BRAINVECTORS | participant | 1.597.783 | 12 |
2012-01-01 | Scaffolds for alternative delivery | SADEL | participant | 4.951.792 | 10 |